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ABSTRACT
Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity 
and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only 
supportive measures were advocated in the treatment of SMA. Recently, Biogen’s Spinraza came out as the first disease modifying therapy to treat 
infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and 
various completed clinical trials as well ongoing clinical trials.
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INTRODUCTION
Spinal muscular atrophy (SMA), a rare autosomal recessive disorder, 
causes debilitating infantile illness ultimately making it the leading 
genetic cause of infantile death. It is very rare with an incidence of 1 in 
100000. SMA 1 gene is associated with the pathogenesis of the disease, 
and this discovery had opened the gates for experimentation of new 
drugs. Recently, in December 2016, Food and Drug Administration 
(FDA) approved Spinraza (Nusinersin) for the treatment of both adult 
and Paediatric SMA.
SMA
The first description of SMA dates back to 19th century, described by 
Werding and Hoffman, when they illustrated cases of motor nerve 
paralysis along with muscle atrophy. Later autopsy revealed severe loss 
of neurons in anterior horn of spinal cord along with atrophic changes 
in the ventral root of the spinal cord, so-called pathological hallmarks 
of SMA [1].
SMA is genetic disorder usually associated with deletions of SMA 
protein in 5q chromosome, so-called 5q SMA or proximal SMA. It 
accounts for 95% of present cases reported leaving behind other 
mutations causing SMA with heterogeneous presentations. SMN 
is the second most common genetic disorder of infancy next only 
to cystic fibrosis with selective damage to spinal neurons causing 
various degrees of muscle wasting mainly starting with lower limbs 
and also associated with other systemic manifestations. Clinical 
manifestations include breathing difficulties, constipation, weight loss, 
Gastroesophageal dysfunction, cardiac abnormalities due to autonomic 
instability, congenital heart defects, muscle wasting, loss of deep 
tendon reflexes and also bulbar and brainstem involvement. SMA is 
divided into five types and characteristics are summarized in Table 1. 
This can be because of SMN gene mutation with deletions in exon 7 or 8. 
Sometimes, it is due to homozygous type having deletion of both SMN 
1 Gene and having two copies of SMN 2 gene. It can be heterozygous 
type with One SMN 1 gene and having mutations in other copy of SMN 
1 gene. For many years, there was no proper disease modifying therapy 
to treat SMA. Only supportive measures were used such as respiratory 
support, nutritional support, physical exercises, and end of life care. 
Various therapies including gene therapy, antisense oligonucleotides, 
small molecules therapy have been tried [1].
Of this Spinraza, the antisense oligonucleotide was successful and was 
approved by FDA on 23.12.2016 and has also been given an orphan 
drug status. The drug was given priority review and fast-track approval 
status and also FDA gave rare pediatric drug review voucher to BIOGEN 
company which they could use for any other product review in future. 
Spinraza is said to be the eight drug to receive rare pediatric review 
voucher from FDA [2].
SPINRAZA
It contains Nusinersin, an antisense oligonucleotide modified with 
phosphate linkages and hydroxyl groups of ribofuranosyl rings being 
replaced with phosphorothioate linkage and methoxyethyl groups, 
respectively. SpinRaza, with a structural formula R = OCH2CH2OCH3, is 
a sterile, colorless solution supplied in single glass vial for intrathecal 
use without addition of any preservatives. The molecular formula is 
C234H323N61O128P17S17NA17 with a molecular weight of 7501.0 daltons. 
1 ml of Spinraza contains 0.22 mg of potassium chloride, 0.21 mg of 
calcium chloride, 0.16 mg of magnesium chloride, 8.22 mg of sodium 
chloride, 0.10 mg of sodium phosphate, and 0.05 mg of sodium 
phosphate monobasic dihydrate. It as a PH OF 7.2 [3].
MECHANISM OF ACTION
It is known with evidence that deficiency of SMN protein is mainly via 
mutations in chromosome 5q. It is shown that SPINRAZA increases 
inclusion of exon 7 in SMN2 messenger ribonucleic acid transcripts. 
Henceforth, it results in production of full-length SMN protein [3].
PHAMACOKINETICS
It is distributed from the CSF to target central nervous system 
tissues when given intrathecally. Trough plasma levels were low 
when compared to trough CSF levels. Median T max ranges from 
1.7 to 6.0 hrs. It is also distributed to liver, kidney, and skeletal muscles. 
It is metabolized by exonucleases mediated hydrolysis. It is neither an 
inhibitor nor an inducer of CYP450 enzymes. Mean elimination half-
lives of Spinraza in CSF and plasma are found to be 135-177 days and 
63-87 days, respectively. The primary mode of elimination is via the 
kidneys with only 0.5% of administered dose excreted in urine [3,4].
DOSAGE AND ADMINISTATION
Recommended dosage is 12 mg (5 ml) per administration. Treatment is 
initiated with 4 loading dose with first three loading doses administered 
at intervals of 14 days followed by 4th dose 30 days after the 3rd dose. 
Maintenance dose is usually once in 4 months. Usually, it is kept at 25°C 
at the time of administration and followed by refrigeration when not 
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used. Discoloration of vial and particulate matter prohibits the use of 
the drug. Spinraza should be administered within 4 hrs once taken out 
of the vial. Proper sedation and ultrasound imaging techniques are used 
to administer drug intrathecally. Before administering the drug, 5 ml 
of cerebrospinal fluid should be removed, and drug is administered 
over 2-3 minutes as intrathecal bolus dose using spinal needle. Avoid 
inflammatory or infectious skin sites [3].
WARNING AND PRECAUTIONS
In a clinical study, 11% of 56 patients developed fall in platelet counts 
below the lower limit of normal compared to none in sham control. 
No patient had sustained platelet count drop despite continued drug 
exposure. Hence, because of thrombocytopenia there is a risk of 
bleeding, so proper monitoring of coagulation profile and platelet 
counts before and after Spinraza is essential.
In a clinical study among patient treated for 7 months, elevation in urine 
protein was found among 33% treated with SpinRaza compared to 
20% of sham control. In those treated for 34 months 69% had elevated 
protein. No elevated of blood urea nitrogen, creatine was noted. Hence, 
since Spinraza causes elevation of protein, spot urine protein testing 
is of prudent importance so as to prevent the patient from acute renal 
toxicity [3].
ADVERSE EFFECTS
Many adverse effects caused by Spinraza are included in (Table 2)
Respiratory complications include pneumonia, bronchiolitis, syncytial 
viral bronchiolitis, pharyngitis, rhinitis, tracheitis, and nasopharyngitis. 
Skin rashes were also noted in few patients, spontaneously resolved. 
Other common adverse effects noted were headache, back pain, 
postlumbar puncture syndrome [5]. Immunogenicity of Spinraza reveals 
production of anti-Spinraza antibodies in few patients, but data are 
insufficient to evaluate the effect of antibodies on clinical response [3].
SPINRAZA IN SPECIFIC POPULATION
1. No teratogenicity was observed in animal studies.
2. In animal models, no embryonal damage or organogenesis was 
affected.
3. In juvenile animal toxicity data in monkeys reveals Spinraza causes 
neuronal vacuolation at hippocampus and transient defects in lower 
spinal reflexes at high doses. Furthermore, learning and memory 
deficits were observed.
4. SMA is disease of adult and children, so no geriatric exposure to this 
drug [3].
CLINICAL TRIALS IN INFANTILE- ONSET SMA
ENDEAR, a multicenter randomized double-blind study with 
121 infants <7 months was started, and an interim analysis was 
done [6]. Scoring was done with Hammersmith Infant Neurologic 
Exam and the Children’s Hospital of Philadelphia infant test of 
neuromuscular disorders [7]. A minimum score of 2 and maximum 
of 26 was given and those who have scores >2 were categorized as 
treatment responders. Responder also needs to fulfill the criteria 
of improvement in motor milestones. Results of interim analysis 
are shown in Table 3. These were supported by open-label trials in 
infants aged from 30 to 15 years in symptomatic SMA and from 8 to 
42 days in case of asymptomatic SMA at the time of the first dose. 
The patients could achieve milestones, some maintained motor 
milestones at ages and some survived to ages. The overall findings 
of the controlled trial in infantile-onset SMA and the open-label 
uncontrolled trials support the effectiveness of SpinRaza across the 
range of SMA patients and appear to support the early initiation of 
treatment with SpinRaza.
SUMMARY OF CLINICAL TRIALS FOR SPINRAZA [1]
• CHERISH (NCT02292537)
 Phase 3 - randomized, sham-controlled trial in children with 
SMA. Positive Interim Results were obtained. The study is closed.
Supporting open-label studies
• SHINE (NCT02594124)
 Phase 3 - open-label extension for participants in ENDEAR and 
CHERISH studies. On-going and recruiting participants.
• EMBRACE (NCT02462759)
 Phase 2 - open-label, multi-dose trial in infants and children who 
did not qualify for ENDEAR or CHERISH. On-going.
• NURTURE (NCT02386553)
 Phase 2 - open-label study in genetically diagnosed pre-
symptomatic infants with SMA on-going.
Table 1: Types and characteristics of SMA
Types of SMA Onset Life expectancy Clinical manifestations
Type 0 In utero, very severe 1 week after birth Failure to swallow and breathe, facial diplegia and joint 
contractures
Type 1 (Werdnig-Hoffman 
disease)
4-5 months, 50% 
patients
2 years of life Floppy infant syndrome along with usual clinical 
manifestations of SMA
Type 2 (Dubowitz disease) 7-18 months 2-40 years Delay of gross motor skills
Type 3 (Kugellberg-Welander 
disease)
18 months - 3 years Life expectancy-general 
population
Muscle hypotonia and wasting
Type 4 Late onset, 3rd 
decade
Life expectancy not 
shortened
Flaccid hypotonia, fasciculation’s, muscular atrophy and 
decreased deep-tendon reflexes, the disease course is 
stable and mild
SMA: Spinal muscular atrophy
Table 2: In controlled study in infants with SMA
Adverse effects Spinraza 12 MG 
(infants with 
SMA) (%)
Control 
patients (%)
Respiratory infections-lower 43 29
Respiratory infections-upper 39 34
Constipation 30 22
Aspiration 5 2
Scoliosis 5 2
Ear infections 5 2
Congestion of URT 6 2
Teething 14 7
SMA: Spinal muscular atrophy
Table 3: Chop-intend results
End point Spinraza 
treated (%)
Sham 
control (%)
Motor milestone 40 (improved) 0
Chop-intend improvement from 
baseline
63 3
Chop-intend worsening 4 40
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• CS3A (NCT01839656)
 Phase 2 - open-label, multi-dose trial in infants with SMA to 
assess tolerability and pharmacokinetics. Completed
• CS12 (NCT02052791)
 Phase 2 - open-label safety and tolerability study in patients with 
SMA who previously participated in the CS2 or CS10 studies. 
Completed
• CS10 (NCT01780246)
 Phase 1 - open-label safety and tolerability study in patients with 
SMA who previously participated in the CS1 study. Completed
• CS2 (NCT01703988)
 Phase 1 - open-label safety, tolerability and dose-range finding 
study of multiple doses in patient with SMA. Completed
• CS1 (NCT01494701)
 Phase 1 - open-label safety, tolerability, and dose-range finding 
study in patients with SMA. Completed
CONCLUSION
Spinraza being a blockbuster drug in the treatment of SMA and with 
pride that it is the only drug approved for adult as well as Paediatric 
SMA makes it very unique. More clinical trials are needed to prove the 
safety and efficacy of this drug and also to look for long- term outcomes 
in the treatment of SMA.
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